Vaccine Committee To Discuss Recommendations and Vote

By U.S. regulatory provisions, the Centers for Disease Control and Prevention (CDC) announced today that the Advisory Committee on Immunization Practices (ACIP) meeting will be open to the public.

As of January 16, 2024, this agenda will include discussions on influenza, chikungunya (IXCHIQ®), COVID–19, meningococcal, pneumococcal, polio, HPV, RSV, combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and Hepatitis B vaccine (Vaxelis®), and vaccines to prevent diphtheria, tetanus, and pertussis.

Recommendation votes are scheduled for influenza vaccines, COVID–19 vaccines, and chikungunya vaccine.

A VFC vote is scheduled for vaccines to prevent diphtheria, tetanus, and pertussis.

The ACIP develops recommendations for U.S. immunizations.

The CDC Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines.

These ACIP meeting agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit https://www.cdc.gov/​vaccines/​acip/​meetings/​index.html.

The ACIP digital meeting will be held on February 28, 2024, from 8 a.m. to 5 p.m. EST and on February 29, 2024, from 8 a.m. to 3 p.m. EST.

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to three minutes, and each speaker may speak only once per meeting.